Frost & Sullivan Honors InfoBionic for New Product Innovation

Wednesday, July 27, 2016 Research News J E 4

Distinction recognizes the superior monitoring efficiency of InfoBionic's proprietary MoMe® Kardia System, which combines the power of cloud computing with continuous arrhythmia monitoring

MOUNTAIN VIEW, California, July 27, 2016 /PRNewswire/ -- Based on its recent analysis of the arrhythmia detection and monitoring market, Frost & Sullivan recognizes InfoBionic with the 2016 North America Frost & Sullivan Award for New Product Innovation. InfoBionic's MoMe® Kardia system plugs the gaps in traditional cardiac arrhythmia detection devices by optimizing its clinical utility for patients and physicians alike. MoMe Kardia is a wireless remote monitoring system that aids in the detection, management, and diagnosis of cardiac arrhythmias.

Photo - 

The MoMe Kardia ambulatory electrocardiograph (ECG) monitoring system is comprised of a wearable MoMe Kardia device that can acquire, store and send full disclosure ECG and other related data. This data is continuously transmitted to the cloud-based MoMe Software System using MoMe Device Communication Protocol. The proprietary software analyzes the data, which can be flagged for physician review on a Web-based physician portal.

The MoMe Kardia system supports the use of three cardiac monitoring modes—Holter monitoring, event monitoring, and mobile cardiovascular telemetry (MCT). One of MoMe Kardia's key features is the MoMe Software System allows for a seamless transition between Holter, event or MCT monitoring, thus eliminating the need to bring the patient back to practice to change technologies.

"Unlike competitors' products that comprises a sensor unit to acquire ECG data and another to transmit the captured data to the monitoring center, the MoMe Kardia system is a single unit," said Frost & Sullivan Senior Research Analyst Karan Verma. "It allows both tasks to be accomplished on a single device, making InfoBionic the first firm to develop a one-stop cardiac monitoring device."

The device has been specially designed for patients who experience transient symptoms of cardiac arrhythmias and require detection and monitoring to guide the choice of drug therapy or the success of a cardiac interventional procedure. The MoMe Kardia system perfectly suits the needs of routine cardiac monitoring as well as an adjunctive device when used in combination with other diagnostic tests.

The MoMe Kardia device has a lightweight, sleek form that makes it extremely portable and facilitates use over long periods. Being a non-invasive device, it poses no significant safety issues to patients. Its proprietary ECG acquisition and transmission technology positions the MoMe Kardia system as an ideal replacement for the complex technologies currently available.

Furthermore, the MoMe Kardia system has developed its own transformative cloud-based proprietary model that powers it to continuously stream and process data. Not only does it deliver data directly to the physician through a secure app that is Health Insurance Portability and Accountability Act (HIPAA)-compliant, it also offers analysis precision by verifying detected events through the algorithm and reduces false positives. The doctor can gain access to this monitoring data at any time of the day, anywhere in the world.

"To complement its cloud-based model, InfoBionic built its very own MoMe Kardia platform as a Software-as-a-Service that is completely scalable to support the growing cardiac monitoring needs of the future, thus minimizing expensive infrastructure costs," noted Karan Verma. "It is evident from InfoBionic's focus on product quality that it has been able to present its product with a full bouquet of features and functionality, giving it an edge over competitors."

InfoBionic is firmly focused on building and strengthening the brand equity of its MoMe Kardia system. The company has already received a TiE50 Award for Top Technology Start-Ups in 2014 and has filed 21 patents for the MoMe Kardia including 6 granted patents and 15 patent applications.

Overall, InfoBionic has done a remarkable job of understanding customer needs in the arrhythmia detection and monitoring market and of developing an innovative new product to address those needs. Its MoMe Kardia system is uniquely positioned for sustained success as it addresses the core issues of quality, functionality, and reliability.

Each year, Frost & Sullivan presents this award to the company that has developed an innovative element in a product by leveraging leading-edge technologies. The award recognizes the value-added features/benefits of the product and the increased ROI it offers customers, which in turn improves customer acquisition and overall market penetration potential.

Frost & Sullivan Best Practices awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research to identify best practices in the industry.

About InfoBionic

InfoBionic is an emerging digital health company focused on creating superior patient monitoring solutions for chronic disease management with an initial market focus on cardiac arrhythmias. For more information please visit

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants.

Our "Growth Partnership" supports clients by addressing these opportunities and incorporating two key elements driving visionary innovation: The Integrated Value Proposition and The Partnership Infrastructure.

  • The Integrated Value Proposition provides support to our clients throughout all phases of their journey to visionary innovation including: research, analysis, strategy, vision, innovation and implementation.
  • The Partnership Infrastructure is entirely unique as it constructs the foundation upon which visionary innovation becomes possible. This includes our 360 degree research, comprehensive industry coverage, career best practices as well as our global footprint of more than 40 offices.

For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organization prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies?

Contact Us:     Start the discussion

Join Us:           Join our community

Subscribe:       Newsletter on "the next big thing"

Register:         Gain access to visionary innovation


Chiara CarellaP: +44 (0) 207.343.8314F: 210.348.1003E:



You May Also Like

View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
Florida Institute Funds Orlando-based Mend VIP
There is No Cure for Alzheimer's. Prevent it Throu...